XDC Academy

Antibody–Radionuclide Conjugates (ARCs) and WuXi XDC’s capabilities in ARCs 

Antibody–Radionuclide Conjugates (ARCs), also known as radioimmunotherapy (RIT), represent a cutting-edge approach to cancer treatment by leveraging antibodies to deliver targeted cytotoxic radiation directly to cancer cells. This innovative strategy is emerging as a highly promising therapeutic modality, offering the potential for enhanced precision and efficacy in oncology.

The ARC field is experiencing rapid growth, with over 150 disclosed assets as of February 2025, including four therapies already approved by regulatory agencies.
 

This slide deck provides a comprehensive overview of ARCs, covering their mechanisms of action, key advantages, competitive landscape, and WuXi XDC’s advanced capabilities in ARC development and other bioconjugate platforms. Discover how WuXi XDC is at the forefront of innovation, driving progress in this transformative therapeutic space.